Document 0517
 DOCN  M9480517
 TI    Transient bacteremia due to Mycobacterium avium complex in patients with
       AIDS.
 DT    9410
 AU    Kemper CA; Havlir D; Bartok AE; Kane C; Camp B; Lane N; Deresinski SC;
       Department of Medicine, Santa Clara Valley Medical Center, San; Jose, CA
       95128.
 SO    J Infect Dis. 1994 Aug;170(2):488-93. Unique Identifier : AIDSLINE
       MED/94308628
 AB    It is generally assumed that Mycobacterium avium complex (MAC)
       bacteremia, once it develops, is unremitting. On the basis of this
       presumption, changes in the level of mycobacteremia are used to gauge
       therapeutic response. In 7 (12%) of 60 patients enrolled in a
       prospective trial of MAC bacteremia and AIDS, bacteremia became
       undetectable before the initiation of antimycobacterial therapy.
       Patients with transient bacteremia reported fewer and shorter symptoms
       and survived longer than those with sustained bacteremia (59 vs. 31
       weeks; P = .022). There was no difference in the duration of AIDS, CD4+
       cell count, hematocrit, or body weight between groups. Two additional
       patients with transient bacteremia were identified outside this study
       setting. Despite disappearance of detectable mycobacteremia and
       subsequent administration of antimycobacterial agent(s), bacteremia once
       again became detectable in 6 patients 4-45 weeks after their negative
       pretreatment cultures. Patients with disseminated MAC may have
       fluctuating levels of mycobacteremia that become undetectable in the
       absence of antimycobacterial therapy.
 DE    Adult  AIDS-Related Opportunistic Infections/DRUG THERAPY/*ETIOLOGY/
       MORTALITY  Bacteremia/DRUG THERAPY/*ETIOLOGY/MORTALITY
       Clofazimine/THERAPEUTIC USE  Drug Therapy, Combination
       Ethambutol/THERAPEUTIC USE  Human  Life Tables  Mycobacterium
       avium-intracellulare Infection/DRUG THERAPY/  *ETIOLOGY/MORTALITY
       Prospective Studies  Recurrence  Rifampin/THERAPEUTIC USE  Risk Factors
       Support, Non-U.S. Gov't  Survival Analysis  CLINICAL TRIAL  JOURNAL
       ARTICLE  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).